Avidity Biosciences (NASDAQ: [[ticker:RNA]]) has added Jae Kim to its C-suite as chief medical officer. Kim most recently served as vice president of clinical development at Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]). His prior experience includes roles at MyoKardia (NASDAQ: [[ticker:MYOK]]) and Amgen (NASDAQ: [[ticker:AMGN]]).
San Diego-based Avidity, which raised a $100 million Series C financing round last November then added nearly $260 million in its initial public offering this June, is developing drugs called antibody-oligonucleotide conjugates to address muscle disorders.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
